CN107709361A - 用于治疗突触核蛋白病的药剂、用途和方法 - Google Patents

用于治疗突触核蛋白病的药剂、用途和方法 Download PDF

Info

Publication number
CN107709361A
CN107709361A CN201680039417.6A CN201680039417A CN107709361A CN 107709361 A CN107709361 A CN 107709361A CN 201680039417 A CN201680039417 A CN 201680039417A CN 107709361 A CN107709361 A CN 107709361A
Authority
CN
China
Prior art keywords
seq
antibody
synuclein
monoclonal antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680039417.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·卡尔伦基
K·福
L·B·韦斯特拉格
A-L·贝里斯特伦
F·索蒂
D·萨蒂恩
E·范登布林克
P·帕伦
R·拉德马克
T·温克
I·J·马里克
L·C·P·蒙特西尼奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CN202511963296.1A priority Critical patent/CN121736097A/zh
Priority to CN202210997939.4A priority patent/CN115925921A/zh
Priority to CN202511963248.2A priority patent/CN121824750A/zh
Publication of CN107709361A publication Critical patent/CN107709361A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
CN201680039417.6A 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法 Pending CN107709361A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202511963296.1A CN121736097A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202210997939.4A CN115925921A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963248.2A CN121824750A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1512203.9 2015-07-13
GBGB1512203.9A GB201512203D0 (en) 2015-07-13 2015-07-13 Agents,uses and methods
PCT/EP2016/066476 WO2017009312A1 (en) 2015-07-13 2016-07-12 Agents, uses and methods for the treatment of synucleinopathy

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202511963296.1A Division CN121736097A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202210997939.4A Division CN115925921A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963248.2A Division CN121824750A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法

Publications (1)

Publication Number Publication Date
CN107709361A true CN107709361A (zh) 2018-02-16

Family

ID=54013851

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201680039417.6A Pending CN107709361A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202210997939.4A Pending CN115925921A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963248.2A Pending CN121824750A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963296.1A Pending CN121736097A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202210997939.4A Pending CN115925921A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963248.2A Pending CN121824750A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法
CN202511963296.1A Pending CN121736097A (zh) 2015-07-13 2016-07-12 用于治疗突触核蛋白病的药剂、用途和方法

Country Status (40)

Country Link
US (12) US10800836B2 (https=)
EP (2) EP4582144A3 (https=)
JP (4) JP7012004B2 (https=)
KR (2) KR20250051158A (https=)
CN (4) CN107709361A (https=)
AR (1) AR105336A1 (https=)
AU (1) AU2016292896B2 (https=)
CL (1) CL2018000075A1 (https=)
CO (1) CO2017012941A2 (https=)
CR (2) CR20180021A (https=)
DK (1) DK3322722T3 (https=)
DO (1) DOP2018000013A (https=)
EA (1) EA036499B1 (https=)
EC (1) ECSP18002645A (https=)
ES (1) ES3028882T3 (https=)
FI (1) FI3322722T3 (https=)
GB (1) GB201512203D0 (https=)
GE (2) GEAP202014670A (https=)
HR (1) HRP20250624T1 (https=)
HU (1) HUE071541T2 (https=)
IL (1) IL256501B (https=)
JO (1) JO3692B1 (https=)
LT (1) LT3322722T (https=)
MA (1) MA42439B1 (https=)
MX (2) MX2018000504A (https=)
MY (1) MY194944A (https=)
NI (1) NI201800006A (https=)
PE (1) PE20181049A1 (https=)
PH (1) PH12018500016A1 (https=)
PL (1) PL3322722T3 (https=)
PT (1) PT3322722T (https=)
RS (1) RS66840B1 (https=)
RU (1) RU2765303C2 (https=)
SI (1) SI3322722T1 (https=)
SV (1) SV2018005612A (https=)
TN (1) TN2018000005A1 (https=)
TW (1) TWI729992B (https=)
UA (1) UA125501C2 (https=)
WO (1) WO2017009312A1 (https=)
ZA (1) ZA201708607B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937210A (zh) * 2016-11-15 2019-06-25 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
CN112839710A (zh) * 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
CN114206444A (zh) * 2019-04-18 2022-03-18 Ac免疫有限公司 用于治疗和诊断的新分子
CN116832057A (zh) * 2023-02-27 2023-10-03 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途
CN117430686A (zh) * 2022-07-22 2024-01-23 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201512203D0 (en) * 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
IL269550B2 (en) 2017-03-27 2025-01-01 Chase Therapeutics Corp Combining a 5HT3 antagonist and pramipexole for the treatment of synucleinopathies
EP3618870A4 (en) * 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
US11155608B2 (en) 2017-08-23 2021-10-26 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological alpha-synuclein, and methods using same
KR102508933B1 (ko) * 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2019147904A1 (en) * 2018-01-26 2019-08-01 Quantum-Si Incorporated Machine learning enabled pulse and base calling for sequencing devices
US20210032369A1 (en) * 2018-02-12 2021-02-04 The Scripps Research Institute Methods related to parkinson?s disease and synucleinopathies
TWI734279B (zh) * 2018-12-14 2021-07-21 美商美國禮來大藥廠 抗α-突觸核蛋白抗體及其用途
JP2022531177A (ja) * 2019-04-29 2022-07-06 トーマス・ジェファーソン・ユニバーシティ 神経変性障害を治療するための方法
CA3159964A1 (en) * 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
KR102466943B1 (ko) * 2020-04-02 2022-11-14 한국과학기술연구원 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템
JP2024534901A (ja) * 2021-09-01 2024-09-26 ヴァクシニティ， インコーポレイテッド シヌクレイノパチーの予防及び治療のための方法
EP4401770A2 (en) 2021-09-16 2024-07-24 H. Lundbeck A/S Compositions and methods for treating synucleinopathies
WO2024177999A2 (en) * 2023-02-21 2024-08-29 The Regents Of The University Of Michigan Human aggregated alpha-synuclein binding molecules
WO2025076635A1 (en) * 2023-10-12 2025-04-17 Universite Laval Anti-alpha-synuclein antibodies and uses thereof
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045037A2 (en) * 2004-10-19 2006-04-27 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
US20090208487A1 (en) * 2003-10-31 2009-08-20 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2013063516A1 (en) * 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
CN103796679A (zh) * 2011-06-23 2014-05-14 比奥根艾迪克国际神经科学公司 抗-α突触核蛋白结合分子
CN104383556A (zh) * 2007-05-16 2015-03-04 布里格姆妇女医院 突触核蛋白病的治疗
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1512203A (en) 1974-05-08 1978-05-24 Aspin F Rolls for use in profiling film
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988004777A1 (en) 1986-12-15 1988-06-30 Ultra Diagnostics Corporation Monomeric phthalocyanine reagents
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
WO1994019935A1 (en) 1993-03-09 1994-09-15 Genzyme Corporation Isolation of components of interest from milk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2002004482A1 (en) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2361928T3 (pl) 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
EA013752B1 (ru) * 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
US20060205024A1 (en) 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
BRPI1015472A2 (pt) 2009-04-09 2015-11-24 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças degenerativas do sistema nervoso central
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP2018515607A (ja) 2015-05-07 2018-06-14 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 神経変性疾患を処置する組成物および方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
US10160800B2 (en) 2016-06-02 2018-12-25 Medimmune Limited Antibodies to α-synuclein and uses thereof
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208487A1 (en) * 2003-10-31 2009-08-20 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006045037A2 (en) * 2004-10-19 2006-04-27 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
CN104383556A (zh) * 2007-05-16 2015-03-04 布里格姆妇女医院 突触核蛋白病的治疗
CN103796679A (zh) * 2011-06-23 2014-05-14 比奥根艾迪克国际神经科学公司 抗-α突触核蛋白结合分子
WO2013063516A1 (en) * 2011-10-28 2013-05-02 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
CN104334184A (zh) * 2011-10-28 2015-02-04 尼奥托普生物科学有限公司 识别α-突触核蛋白的人源化抗体
WO2015075011A1 (en) * 2013-11-21 2015-05-28 F. Hoffmann-La Roche Ag ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAKES R等: "Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein", 《NEUROSCIENCE LETTERS》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937210A (zh) * 2016-11-15 2019-06-25 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法
CN109937210B (zh) * 2016-11-15 2023-09-15 H.隆德贝克有限公司 用于治疗共核蛋白病的药剂、用途和方法
CN112839710A (zh) * 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
CN114206444A (zh) * 2019-04-18 2022-03-18 Ac免疫有限公司 用于治疗和诊断的新分子
CN114206444B (zh) * 2019-04-18 2026-01-06 Ac免疫有限公司 用于治疗和诊断的新分子
CN111537738A (zh) * 2020-05-18 2020-08-14 南通大学附属医院 用于超早期帕金森病检测的试剂盒
CN117430686A (zh) * 2022-07-22 2024-01-23 深圳市安群生物工程有限公司 α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用
CN116832057A (zh) * 2023-02-27 2023-10-03 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途

Also Published As

Publication number Publication date
MY194944A (en) 2022-12-27
HRP20250624T1 (hr) 2025-07-18
AU2016292896B2 (en) 2022-02-24
US10647764B2 (en) 2020-05-12
US20210061892A1 (en) 2021-03-04
KR102793383B1 (ko) 2025-04-08
WO2017009312A1 (en) 2017-01-19
CN121824750A (zh) 2026-04-10
EP3322722A1 (en) 2018-05-23
GEAP202014670A (en) 2020-05-11
CA2989735A1 (en) 2017-01-19
ECSP18002645A (es) 2018-03-31
CN121736097A (zh) 2026-03-27
CO2017012941A2 (es) 2018-03-09
MX2018000504A (es) 2018-04-30
US20180127492A1 (en) 2018-05-10
US10800836B2 (en) 2020-10-13
US11542323B2 (en) 2023-01-03
JP7138322B2 (ja) 2022-09-16
US20210147522A1 (en) 2021-05-20
IL256501B (en) 2021-10-31
US11524995B2 (en) 2022-12-13
KR20180029205A (ko) 2018-03-20
EP4582144A3 (en) 2025-07-16
HUE071541T2 (hu) 2025-09-28
US20190367595A1 (en) 2019-12-05
US20210054057A1 (en) 2021-02-25
CL2018000075A1 (es) 2018-05-11
CR20230300A (es) 2023-08-25
PT3322722T (pt) 2025-05-21
MA42439B1 (fr) 2025-05-30
RS66840B1 (sr) 2025-06-30
JP7608404B2 (ja) 2025-01-06
MA42439A (fr) 2018-05-23
BR112017027506A2 (pt) 2018-09-11
US20180179271A1 (en) 2018-06-28
SV2018005612A (es) 2018-07-20
UA125501C2 (uk) 2022-04-13
US10358483B2 (en) 2019-07-23
NI201800006A (es) 2018-10-18
RU2017145653A3 (https=) 2019-11-21
EA201792616A1 (ru) 2018-06-29
CN115925921A (zh) 2023-04-07
PH12018500016A1 (en) 2018-07-09
US20180127491A1 (en) 2018-05-10
GEP20207151B (en) 2020-09-25
JP2022174131A (ja) 2022-11-22
US20180179270A1 (en) 2018-06-28
DOP2018000013A (es) 2018-04-15
RU2765303C2 (ru) 2022-01-28
JP2025041734A (ja) 2025-03-26
GB201512203D0 (en) 2015-08-19
JP2018529634A (ja) 2018-10-11
US10647763B2 (en) 2020-05-12
JP7012004B2 (ja) 2022-02-10
US20190367594A1 (en) 2019-12-05
US11421024B2 (en) 2022-08-23
US20170015739A1 (en) 2017-01-19
NZ738315A (en) 2024-12-20
PL3322722T3 (pl) 2025-06-30
ZA201708607B (en) 2019-05-29
TN2018000005A1 (en) 2019-07-08
JP2021191763A (ja) 2021-12-16
DK3322722T3 (da) 2025-05-26
HK1254358A1 (en) 2019-07-19
TW201716440A (zh) 2017-05-16
CR20180021A (es) 2018-03-13
US10358484B2 (en) 2019-07-23
US10358482B2 (en) 2019-07-23
US20190382473A1 (en) 2019-12-19
MX2023009483A (es) 2023-08-22
TWI729992B (zh) 2021-06-11
FI3322722T3 (fi) 2025-06-05
KR20250051158A (ko) 2025-04-16
IL256501A (en) 2018-02-28
EP3322722B1 (en) 2025-03-05
SI3322722T1 (sl) 2025-06-30
JO3692B1 (ar) 2020-08-27
LT3322722T (lt) 2025-06-10
AU2016292896A1 (en) 2018-01-18
EA036499B1 (ru) 2020-11-17
RU2017145653A (ru) 2019-08-13
US10364285B2 (en) 2019-07-30
AR105336A1 (es) 2017-09-27
ES3028882T3 (en) 2025-06-20
PE20181049A1 (es) 2018-07-03
US10640554B2 (en) 2020-05-05
US20230312693A1 (en) 2023-10-05
EP4582144A2 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
US11421024B2 (en) Agents, uses and methods for the treatment of synucleinopathy
CN109937210A (zh) 用于治疗共核蛋白病的药剂、用途和方法
HK40127009A (en) Agents, uses and methods for the treatment of synucleinopathy
CA2989735C (en) Antibodies binding alpha-synuclein and uses thereof for the treatment of synucleinopathy
HK1254358B (en) Agents, uses and methods for the treatment of synucleinopathy
BR112017027506B1 (pt) Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo, preparação, composição farmacêutica, uso dos mesmos e kit para o tratamento de sinucleinopatia
OA18689A (en) Agents, Uses and Methods for the Treatment of Synucleinopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: P. Karlenki

Inventor after: T Winkler

Inventor after: I.J. Malik

Inventor after: L - C - P - Mountsea Mourinho

Inventor after: J - B - stavenhagen

Inventor after: K.Fu

Inventor after: L. B. West lager

Inventor after: Tony Rees Trent A-L

Inventor after: F sauty

Inventor after: D. Satien

Inventor after: E. Van den Brink

Inventor after: P. Palen

Inventor after: R. Rademark

Inventor before: P. Karlenki

Inventor before: T Winkler

Inventor before: I.J. Malik

Inventor before: L - C - P - Mountsea Mourinho

Inventor before: K.Fu

Inventor before: L. B. West lager

Inventor before: Tony Rees Trent A-L

Inventor before: F sauty

Inventor before: D. Satien

Inventor before: E. Van den Brink

Inventor before: P. Palen

Inventor before: R. Rademark

CB03 Change of inventor or designer information